I Just Bought My First New Stock in 8 Months, and This Is It

I Just Bought My First New Stock in 8 Months, and This Is It

I’d like to think all investors are picky to some degree, otherwise we’d simply throw a dart at a newspaper and buy whatever it lands on. But some of us are pickier than others — and I certainly would lump myself in that crowd. Since September, when I bought my first shares of Intercept Pharmaceuticals, […]

Recro Pharma Receives Complete Response Letter from the FDA

Recro Pharma Receives Complete Response Letter from the FDA

MALVERN, Penn., May 24, 2018 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) Office of Drug Evaluation II regarding the New Drug Application […]

Verastem Oncology Announces Closing of Underwriter's Option to Purchase Additional Shares

Verastem Oncology Announces Closing of Underwriter's Option to Purchase Additional Shares

BOSTON–(BUSINESS WIRE)–May 23, 2018–Verastem, Inc., (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has issued 1,166,666 shares of the Company’s common stock at a price to the public of $4.50 per share, pursuant to the full […]

FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin …

FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin …

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with transthyretin cardiomyopathy, a rare, fatal, and underdiagnosed condition associated with progressive heart failure.1,2 This decision is supported by topline results from the tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) […]

New drug targets pain from foot rot in cattle

New drug targets pain from foot rot in cattle

A new topical drug promising pain relief from a specific ailment affecting cattle is now available in Canada. Banamine transdermal, a non-steroidal anti-inflammatory drug (NSAID) produced by Merck Animal Health, was released at the end of January. This pour-on product, with flunixin meglumine as the active ingredient, is used to reduce fever related to bovine […]

Cannabis Industry Projected to Experience Significant Growth While Legalization Efforts Pick Up Steam

Cannabis Industry Projected to Experience Significant Growth While Legalization Efforts Pick Up Steam

The multi-billion dollar cannabis industry is projected to experience 28% CAGR through 2021 en route to nearly $25 billion in annual revenues, according to a study conducted by Cannabis Business Plan. States with large populations like Florida and Arizona are expected to make legalization progress within the next five years, leading to a more competitive, […]

FDA to respond to Teva migraine drug application in Sep

FDA to respond to Teva migraine drug application in Sep

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today confirmed that the US Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for migraine treatment fremanezumab. The Prescription Drug User Fee Act (PDUFA) action date for fremanezumab is set for September 16, 2018. There are no additional […]

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical …

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical …

DepressionClinical data for ALKS 5461 will be presented, including long-term safety, tolerability and durability of antidepressant effect over a 52-week treatment period in patients with major depressive disorder (MDD). In addition, data from a human abuse potential study conducted in healthy, nondependent opioid users will be presented. In the study, ALKS 5461, a combination of […]

Global Growth Factors (Blood and Tissue) Strategic Business Report 2018: Expanding Pool of ESRD and CKD Patients …

Global Growth Factors (Blood and Tissue) Strategic Business Report 2018: Expanding Pool of ESRD and CKD Patients …

May 23, 2018 05:01 ET | Source: Research and Markets Dublin, May 23, 2018 (GLOBE NEWSWIRE) — The “Growth Factors (Blood and Tissue) – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. […]

1 2 3 24